These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33119722)

  • 1. Extent of arterial calcification by conventional vitamin K antagonist treatment.
    Hasific S; Øvrehus KA; Gerke O; Hallas J; Busk M; Lambrechtsen J; Urbonaviciene G; Sand NPR; Nielsen JS; Diederichsen L; Pedersen KB; Carter-Storch R; Ilangkovan N; Mickley H; Rasmussen LM; Lindholt JS; Diederichsen A
    PLoS One; 2020; 15(10):e0241450. PubMed ID: 33119722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of aortic valve calcification and vitamin K antagonist treatment.
    Sønderskov PS; Lindholt JS; Hallas J; Gerke O; Hasific S; Lambrechtsen J; Steffensen FH; Busk M; Frost L; Urbonaviciene G; Karon M; Kikar AM; Rasmussen LM; Diederichsen AA
    Eur Heart J Cardiovasc Imaging; 2020 Jul; 21(7):718-724. PubMed ID: 32361722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)].
    Sucker C; Litmathe J; Berthold HK
    MMW Fortschr Med; 2019 Oct; 161(Suppl 6):15-23. PubMed ID: 31587168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin K Antagonists, Non-Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation.
    Peeters FECM; Dudink EAMP; Kimenai DM; Weijs B; Altintas S; Heckman LIB; Mihl C; Schurgers LJ; Wildberger JE; Meex SJR; Kietselaer BLJH; Crijns HJGM
    TH Open; 2018 Oct; 2(4):e391-e398. PubMed ID: 31249966
    [No Abstract]   [Full Text] [Related]  

  • 5. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
    Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
    Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
    Gorczyca-Michta I; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
    Schurgers LJ; Joosen IA; Laufer EM; Chatrou ML; Herfs M; Winkens MH; Westenfeld R; Veulemans V; Krueger T; Shanahan CM; Jahnen-Dechent W; Biessen E; Narula J; Vermeer C; Hofstra L; Reutelingsperger CP
    PLoS One; 2012; 7(8):e43229. PubMed ID: 22952653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban versus vitamin K antagonist treatment on the progression of coronary calcification: the IRIVASC-trial.
    Stöhr R; Reinartz S; Dirrichs T; Witte K; Schuh A; Brandenburg V
    Sci Rep; 2024 Jul; 14(1):17605. PubMed ID: 39080305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
    Fosbøl EL; Vinding NE; Lamberts M; Staerk L; Gundlund A; Gadsbøll K; Køber L; Gislason GH; Olesen JB
    Europace; 2018 Jun; 20(6):e78-e86. PubMed ID: 28666358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage.
    Gerner ST; Kuramatsu JB; Sembill JA; Sprügel MI; Hagen M; Knappe RU; Endres M; Haeusler KG; Sobesky J; Schurig J; Zweynert S; Bauer M; Vajkoczy P; Ringleb PA; Purrucker JC; Rizos T; Volkmann J; Müllges W; Kraft P; Schubert AL; Erbguth F; Nueckel M; Schellinger PD; Glahn J; Knappe UJ; Fink GR; Dohmen C; Stetefeld H; Fisse AL; Minnerup J; Hagemann G; Rakers F; Reichmann H; Schneider H; Rahmig J; Ludolph AC; Stösser S; Neugebauer H; Röther J; Michels P; Schwarz M; Reimann G; Bäzner H; Schwert H; Claßen J; Michalski D; Grau A; Palm F; Urbanek C; Wöhrle JC; Alshammari F; Horn M; Bahner D; Witte OW; Günther A; Hamann GF; Engelhorn T; Lücking H; Dörfler A; Schwab S; Huttner HB
    Stroke; 2019 Jun; 50(6):1392-1402. PubMed ID: 31092170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding complications with oral anticoagulants in the elderly: an observational study.
    Peeterbroeck J; Danguy C; Lelubre C; Meulemans M; Higuet S
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Dec; 14(4):406-412. PubMed ID: 27507064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A
    Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture.
    Fiordellisi W; White K; Schweizer M
    J Gen Intern Med; 2019 Feb; 34(2):304-311. PubMed ID: 30511289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC Trial).
    Vossen LM; Schurgers LJ; van Varik BJ; Kietselaer BL; Vermeer C; Meeder JG; Rahel BM; van Cauteren YJ; Hoffland GA; Rennenberg RJ; Reesink KD; de Leeuw PW; Kroon AA
    Nutrients; 2015 Oct; 7(11):8905-15. PubMed ID: 26516910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vascular calcifications, the hidden side effects of vitamin K antagonists].
    Bennis Y; Vengadessane S; Bodeau S; Gras V; Bricca G; Kamel S; Liabeuf S
    Therapie; 2016 Sep; 71(4):355-63. PubMed ID: 27203170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial calcifications under vitamin K antagonists or direct oral anticoagulants: Results from the French VIKING study in older adults.
    Annweiler G; Labriffe M; Ménager P; Ferland G; Brangier A; Annweiler C;
    Maturitas; 2020 Feb; 132():35-39. PubMed ID: 31883661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.